Rani Therapeutics gets Nasdaq extension to May 10, 2027, to meet minimum bid price requirement
RANI•Nasdaq gave Rani Therapeutics until May 10, 2027, to regain compliance with its minimum bid price requirement. The company must maintain a closing bid of at least $1 per share for 10 consecutive business days and may use a reverse stock split if necessary.
1. Nasdaq compliance extension
Nasdaq granted Rani Therapeutics an additional 180 days, until May 10, 2027, to regain compliance with its minimum bid price requirement. Its Class A common stock moved from the Nasdaq Global Market to the Nasdaq Capital Market effective November 12, 2026. Compliance requires a closing bid price of at least $1 per share for at least 10 consecutive business days; the company committed to curing the deficiency, including through a reverse stock split if necessary.
